The Board of Directors of Anthem Biosciences Limited met on February 05, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. For the quarter ended December 31, 2025 (Q3 FY26), the company reported a revenue from operations of ₹4,231.53 million, representing a decline of 23.07% compared to ₹5,500.27 million in the previous quarter (Q2 FY26). When compared to the corresponding quarter of the previous year (Q3 FY25), revenue decreased by 15.00% from ₹4,978.06 million. The net profit for Q3 FY26 stood at ₹1,133.00 million, a decrease of 34.67% from the ₹1,734.30 million recorded in the previous quarter, and a 27.24% decline from ₹1,557.14 million in the same quarter last year.

Anthem Biosciences Limited, incorporated in 2006, is a premier Bengaluru-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in both small molecules and biologics. In July 2025, the company successfully launched its ₹3,395 crore Initial Public Offering (IPO), debuting on the BSE and NSE on July 21, 2025. A key milestone in 2025 was the phased operationalization of its “NeoAnthem” (Unit III) greenfield facility in Harohalli, aimed at expanding its fermentation and custom synthesis capacities. The company has attracted prominent investors, including Quant Mutual Fund (Quant Mid Cap Fund), which held a 1.62% stake as of December 2025, alongside institutional interest from firms like Portsmouth Technologies LLC and Viridity Tone LLP. Anthem remains a leader in high-growth niche segments such as GLP-1 and biosimilars, driven by its 1,500-strong team of scientists and engineers.